Answers are grounded in this paper and cite their sources.
To systematically evaluate the efficacy and safety of Sodium Cantharidinate and Vitamin B6 Injection (SC/B6) combined with intrapleural perfusion of cytotoxic chemotherapeutic agents in the treatment of malignant pleural effusion (MPE). PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP databases from database inception to September 2026 to identify randomized controlled trials (RCTs) on SC/B6 combined with intrapleural perfusion of cytotoxic chemotherapeutic agents for MPE. Two reviewers independently screened the literature, extracted data, and assessed the risk of bias. Meta-analysis was performed using RevMan 5.4 software and STATA 12. A total of 9 RCTs involving 718 patients were included. Meta-analysis showed that compared with intrapleural perfusion with cytotoxic chemotherapeutic agents alone, the SC/B6 combination group significantly improved the complete response rate [RR = 1.83, 95% CI (1.45, 2.32), p < 0.00001], partial response rate [RR = 1.23, 95% CI (1.01, 1.50), p = 0.04], and overall response rate [RR = 1.47, 95% CI (1.31, 1.64), p < 0.00001], disease control rate [RR = 1.13, 95% CI (1.01, 1.26), p = 0.04], and significantly improved quality of life [RR = 1.44, 95% CI (1.20, 1.72), p < 0.0001]. In terms of safety, the combination group did not significantly increase the risks of gastrointestinal reactions [RR = 0.79, 95% CI (0.59, 1.06), p = 0.12], myelosuppression [RR = 0.83, 95% CI (0.61, 1.12), p = 0.22], chest pain [RR = 0.91, 95% CI (0.68, 1.22), p = 0.53], or fever [RR = 0.90, 95% CI (0.70, 1.16), p = 0.42]. Sensitivity analysis showed that the results were robust, and Egger’s test indicated no significant publication bias ( p = 0.520). SC/B6 combined with intrapleural perfusion of cytotoxic chemotherapeutic agents can improve short-term objective response rates and quality of life in patients with MPE without significantly increasing major adverse reactions, and may serve as a local palliative treatment option; however, due to the lack of long-term survival data, its long-term benefit still requires further validation.
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: